The immunometabolic ecosystem in cancer.
Journal
Nature immunology
ISSN: 1529-2916
Titre abrégé: Nat Immunol
Pays: United States
ID NLM: 100941354
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
20
04
2023
accepted:
03
10
2023
medline:
29
11
2023
pubmed:
28
11
2023
entrez:
27
11
2023
Statut:
ppublish
Résumé
Our increased understanding of how key metabolic pathways are activated and regulated in malignant cells has identified metabolic vulnerabilities of cancers. Translating this insight to the clinics, however, has proved challenging. Roadblocks limiting efficacy of drugs targeting cancer metabolism may lie in the nature of the metabolic ecosystem of tumors. The exchange of metabolites and growth factors between cancer cells and nonmalignant tumor-resident cells is essential for tumor growth and evolution, as well as the development of an immunosuppressive microenvironment. In this Review, we will examine the metabolic interplay between tumor-resident cells and how targeted inhibition of specific metabolic enzymes in malignant cells could elicit pro-tumorigenic effects in non-transformed tumor-resident cells and inhibit the function of tumor-specific T cells. To improve the efficacy of metabolism-targeted anticancer strategies, a holistic approach that considers the effect of metabolic inhibitors on major tumor-resident cell populations is needed.
Identifiants
pubmed: 38012409
doi: 10.1038/s41590-023-01675-y
pii: 10.1038/s41590-023-01675-y
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2008-2020Informations de copyright
© 2023. Springer Nature America, Inc.
Références
Holt, R. D. Bringing the Hutchinsonian niche into the 21st century: ecological and evolutionary perspectives. Proc. Natl Acad. Sci. USA 106, 19659–19665 (2009).
pubmed: 19903876
pmcid: 2780934
doi: 10.1073/pnas.0905137106
Kalluri, R. The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 16, 582–598 (2016).
pubmed: 27550820
doi: 10.1038/nrc.2016.73
Vitale, I., Manic, G., Coussens, L. M., Kroemer, G. & Galluzzi, L. Macrophages and metabolism in the tumor microenvironment. Cell Metab. 30, 36–50 (2019).
pubmed: 31269428
doi: 10.1016/j.cmet.2019.06.001
Philip, M. & Schietinger, A. CD8
pubmed: 34253904
doi: 10.1038/s41577-021-00574-3
Stine, Z. E., Schug, Z. T., Salvino, J. M. & Dang, C. V. Targeting cancer metabolism in the era of precision oncology. Nat. Rev. Drug Discov. 21, 141–162 (2022).
pubmed: 34862480
doi: 10.1038/s41573-021-00339-6
Vasan, K., Werner, M. & Chandel, N. S. Mitochondrial metabolism as a target for cancer therapy. Cell Metab. 32, 341–352 (2020).
pubmed: 32668195
pmcid: 7483781
doi: 10.1016/j.cmet.2020.06.019
Zhang, X. & Dang, C. V. Time to hit pause on mitochondria-targeting cancer therapies. Nat. Med. 29, 29–30 (2023).
pubmed: 36658424
doi: 10.1038/s41591-022-02129-y
Pavlova, N. N., Zhu, J. & Thompson, C. B. The hallmarks of cancer metabolism: still emerging. Cell Metab. 34, 355–377 (2022).
pubmed: 35123658
pmcid: 8891094
doi: 10.1016/j.cmet.2022.01.007
Vyas, S., Zaganjor, E. & Haigis, M. C. Mitochondria and cancer. Cell 166, 555–566 (2016).
pubmed: 27471965
pmcid: 5036969
doi: 10.1016/j.cell.2016.07.002
Le, A. et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc. Natl Acad. Sci. USA 107, 2037–2042 (2010).
pubmed: 20133848
pmcid: 2836706
doi: 10.1073/pnas.0914433107
Hensley, C. T. et al. Metabolic heterogeneity in human lung tumors. Cell 164, 681–694 (2016).
pubmed: 26853473
pmcid: 4752889
doi: 10.1016/j.cell.2015.12.034
Davidson, S. M. et al. Environment impacts the metabolic dependencies of ras-driven non-small cell lung cancer. Cell Metab. 23, 517–528 (2016).
pubmed: 26853747
pmcid: 4785096
doi: 10.1016/j.cmet.2016.01.007
Sellers, K. et al. Pyruvate carboxylase is critical for non-small-cell lung cancer proliferation. J. Clin. Invest. 125, 687–698 (2015).
pubmed: 25607840
pmcid: 4319441
doi: 10.1172/JCI72873
Faubert, B. et al. Lactate metabolism in human lung tumors. Cell 171, 358–371 (2017).
pubmed: 28985563
pmcid: 5684706
doi: 10.1016/j.cell.2017.09.019
Hui, S. et al. Glucose feeds the TCA cycle via circulating lactate. Nature 551, 115–118 (2017).
pubmed: 29045397
pmcid: 5898814
doi: 10.1038/nature24057
Payen, V. L., Mina, E., Van Hee, V. F., Porporato, P. E. & Sonveaux, P. Monocarboxylate transporters in cancer. Mol. Metab. 33, 48–66 (2020).
pubmed: 31395464
doi: 10.1016/j.molmet.2019.07.006
Knudsen, E. S., Balaji, U., Freinkman, E., McCue, P. & Witkiewicz, A. K. Unique metabolic features of pancreatic cancer stroma: relevance to the tumor compartment, prognosis, and invasive potential. Oncotarget 7, 78396–78411 (2016).
pubmed: 27623078
pmcid: 5346648
doi: 10.18632/oncotarget.11893
Bartman, C. R. et al. Slow TCA flux and ATP production in primary solid tumours but not metastases. Nature 614, 349–357 (2023).
pubmed: 36725930
pmcid: 10288502
doi: 10.1038/s41586-022-05661-6
Birsoy, K. et al. An essential role of the mitochondrial electron transport chain in cell proliferation is to enable aspartate synthesis. Cell 162, 540–551 (2015).
pubmed: 26232224
pmcid: 4522279
doi: 10.1016/j.cell.2015.07.016
Hatzivassiliou, G. et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8, 311–321 (2005).
pubmed: 16226706
doi: 10.1016/j.ccr.2005.09.008
Yang, Y. et al. SLC25A1 promotes tumor growth and survival by reprogramming energy metabolism in colorectal cancer. Cell Death Dis. 12, 1108 (2021).
pubmed: 34839347
pmcid: 8627508
doi: 10.1038/s41419-021-04411-2
Zaidi, N., Swinnen, J. V. & Smans, K. ATP-citrate lyase: a key player in cancer metabolism. Cancer Res. 72, 3709–3714 (2012).
pubmed: 22787121
doi: 10.1158/0008-5472.CAN-11-4112
Martinez-Reyes, I. & Chandel, N. S. Mitochondrial TCA cycle metabolites control physiology and disease. Nat. Commun. 11, 102 (2020).
pubmed: 31900386
pmcid: 6941980
doi: 10.1038/s41467-019-13668-3
Wellen, K. E. et al. ATP-citrate lyase links cellular metabolism to histone acetylation. Science 324, 1076–1080 (2009).
pubmed: 19461003
pmcid: 2746744
doi: 10.1126/science.1164097
Carey, B. W., Finley, L. W., Cross, J. R., Allis, C. D. & Thompson, C. B. Intracellular alpha-ketoglutarate maintains the pluripotency of embryonic stem cells. Nature 518, 413–416 (2015).
pubmed: 25487152
doi: 10.1038/nature13981
Sciacovelli, M. et al. Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition. Nature 537, 544–547 (2016).
pubmed: 27580029
pmcid: 5136292
doi: 10.1038/nature19353
Xiao, M. et al. Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev. 26, 1326–1338 (2012).
pubmed: 22677546
pmcid: 3387660
doi: 10.1101/gad.191056.112
Burnichon, N. et al. SDHA is a tumor suppressor gene causing paraganglioma. Hum. Mol. Genet 19, 3011–3020 (2010).
pubmed: 20484225
pmcid: 2901140
doi: 10.1093/hmg/ddq206
Cervera, A. M., Bayley, J. P., Devilee, P. & McCreath, K. J. Inhibition of succinate dehydrogenase dysregulates histone modification in mammalian cells. Mol. Cancer 8, 89 (2009).
pubmed: 19849834
pmcid: 2770992
doi: 10.1186/1476-4598-8-89
Letouze, E. et al. SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell 23, 739–752 (2013).
pubmed: 23707781
doi: 10.1016/j.ccr.2013.04.018
Burgener, A. V. et al. SDHA gain-of-function engages inflammatory mitochondrial retrograde signaling via KEAP1-Nrf2. Nat. Immunol. 20, 1311–1321 (2019).
pubmed: 31527833
doi: 10.1038/s41590-019-0482-2
Kinch, L., Grishin, N. V. & Brugarolas, J. Succination of Keap1 and activation of Nrf2-dependent antioxidant pathways in FH-deficient papillary renal cell carcinoma type 2. Cancer Cell 20, 418–420 (2011).
pubmed: 22014567
pmcid: 3226726
doi: 10.1016/j.ccr.2011.10.005
Hollinshead, K. E. R. et al. Respiratory supercomplexes promote mitochondrial efficiency and growth in severely hypoxic pancreatic cancer. Cell Rep. 33, 108231 (2020).
pubmed: 33027658
pmcid: 7573785
doi: 10.1016/j.celrep.2020.108231
Molina, J. R. et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat. Med. 24, 1036–1046 (2018).
pubmed: 29892070
doi: 10.1038/s41591-018-0052-4
Lee, K. M. et al. MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation. Cell Metab. 26, 633–647 (2017).
pubmed: 28978427
pmcid: 5650077
doi: 10.1016/j.cmet.2017.09.009
Ohlund, D. et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J. Exp. Med. 214, 579–596 (2017).
pubmed: 28232471
pmcid: 5339682
doi: 10.1084/jem.20162024
Elyada, E. et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov. 9, 1102–1123 (2019).
pubmed: 31197017
pmcid: 6727976
doi: 10.1158/2159-8290.CD-19-0094
Hu, B. et al. Subpopulations of cancer-associated fibroblasts link the prognosis and metabolic features of pancreatic ductal adenocarcinoma. Ann. Transl. Med. 10, 262 (2022).
pubmed: 35402584
pmcid: 8987890
doi: 10.21037/atm-22-407
Li, Z., Sun, C. & Qin, Z. Metabolic reprogramming of cancer-associated fibroblasts and its effect on cancer cell reprogramming. Theranostics 11, 8322–8336 (2021).
pubmed: 34373744
pmcid: 8343997
doi: 10.7150/thno.62378
Becker, L. M. et al. Epigenetic reprogramming of cancer-associated fibroblasts deregulates glucose metabolism and facilitates progression of breast cancer. Cell Rep. 31, 107701 (2020).
pubmed: 32492417
pmcid: 7339325
doi: 10.1016/j.celrep.2020.107701
Fiaschi, T. et al. Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor–stroma interplay. Cancer Res. 72, 5130–5140 (2012).
pubmed: 22850421
doi: 10.1158/0008-5472.CAN-12-1949
Parker, S. J. et al. Selective alanine transporter utilization creates a targetable metabolic niche in pancreatic cancer. Cancer Discov. 10, 1018–1037 (2020).
pubmed: 32341021
pmcid: 7334074
doi: 10.1158/2159-8290.CD-19-0959
Sousa, C. M. et al. Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature 536, 479–483 (2016).
pubmed: 27509858
pmcid: 5228623
doi: 10.1038/nature19084
Yang, L. et al. Targeting stromal glutamine synthetase in tumors disrupts tumor microenvironment-regulated cancer cell growth. Cell Metab. 24, 685–700 (2016).
pubmed: 27829138
pmcid: 7329194
doi: 10.1016/j.cmet.2016.10.011
Ippolito, L. et al. Cancer-associated fibroblasts promote prostate cancer malignancy via metabolic rewiring and mitochondrial transfer. Oncogene 38, 5339–5355 (2019).
pubmed: 30936458
doi: 10.1038/s41388-019-0805-7
Bhagat, T. D. et al. Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts. Elife 8, e50663 (2019).
pubmed: 31663852
pmcid: 6874475
doi: 10.7554/eLife.50663
Smith, E. R. & Hewitson, T. D. TGF-β1 is a regulator of the pyruvate dehydrogenase complex in fibroblasts. Sci. Rep. 10, 17914 (2020).
pubmed: 33087819
pmcid: 7578649
doi: 10.1038/s41598-020-74919-8
Comito, G. et al. Lactate modulates CD4
pubmed: 30664688
doi: 10.1038/s41388-019-0688-7
Watson, M. J. et al. Metabolic support of tumour-infiltrating regulatory T cells by lactic acid. Nature 591, 645–651 (2021).
pubmed: 33589820
pmcid: 7990682
doi: 10.1038/s41586-020-03045-2
Mendler, A. N. et al. Tumor lactic acidosis suppresses CTL function by inhibition of p38 and JNK/c-Jun activation. Int. J. Cancer 131, 633–640 (2012).
pubmed: 21898391
doi: 10.1002/ijc.26410
Chang, C. H. et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162, 1229–1241 (2015).
pubmed: 26321679
pmcid: 4864363
doi: 10.1016/j.cell.2015.08.016
Colegio, O. R. et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 513, 559–563 (2014).
pubmed: 25043024
pmcid: 4301845
doi: 10.1038/nature13490
Noe, J. T. et al. Lactate supports a metabolic-epigenetic link in macrophage polarization. Sci. Adv. 7, eabi8602 (2021).
pubmed: 34767443
pmcid: 8589316
doi: 10.1126/sciadv.abi8602
Liu, P. S. et al. α-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming. Nat. Immunol. 18, 985–994 (2017).
pubmed: 28714978
doi: 10.1038/ni.3796
Bohn, T. et al. Tumor immunoevasion via acidosis-dependent induction of regulatory tumor-associated macrophages. Nat. Immunol. 19, 1319–1329 (2018).
pubmed: 30397348
doi: 10.1038/s41590-018-0226-8
Chang, C. H. et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 153, 1239–1251 (2013).
pubmed: 23746840
pmcid: 3804311
doi: 10.1016/j.cell.2013.05.016
Gubser, P. M. et al. Rapid effector function of memory CD8
pubmed: 23955661
doi: 10.1038/ni.2687
Baitsch, L. et al. Exhaustion of tumor-specific CD8
pubmed: 21555851
pmcid: 3104769
doi: 10.1172/JCI46102
Zheng, L. et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. Science 374, abe6474 (2021).
pubmed: 34914499
doi: 10.1126/science.abe6474
Buck, M. D. et al. Mitochondrial dynamics controls T cell fate through metabolic programming. Cell 166, 63–76 (2016).
pubmed: 27293185
pmcid: 4974356
doi: 10.1016/j.cell.2016.05.035
Scharping, N. E. et al. The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction. Immunity 45, 374–388 (2016).
pubmed: 27496732
pmcid: 5207350
doi: 10.1016/j.immuni.2016.07.009
Scharping, N. E. et al. Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Nat. Immunol. 22, 205–215 (2021).
pubmed: 33398183
pmcid: 7971090
doi: 10.1038/s41590-020-00834-9
Siska, P. J. et al. Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma. JCI Insight 2, e93411 (2017).
pubmed: 28614802
pmcid: 5470888
doi: 10.1172/jci.insight.93411
Vardhana, S. A. et al. Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen. Nat. Immunol. 21, 1022–1033 (2020).
pubmed: 32661364
pmcid: 7442749
doi: 10.1038/s41590-020-0725-2
Yu, Y. R. et al. Disturbed mitochondrial dynamics in CD8
pubmed: 33020660
doi: 10.1038/s41590-020-0793-3
Dumauthioz, N. et al. Enforced PGC-1α expression promotes CD8 T cell fitness, memory formation and antitumor immunity. Cell Mol. Immunol. 18, 1761–1771 (2021).
pubmed: 32055005
doi: 10.1038/s41423-020-0365-3
Chamoto, K. et al. Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity. Proc. Natl Acad. Sci. USA 114, E761–E770 (2017).
pubmed: 28096382
pmcid: 5293087
doi: 10.1073/pnas.1620433114
Ogando, J. et al. PD-1 signaling affects cristae morphology and leads to mitochondrial dysfunction in human CD8
pubmed: 31196176
pmcid: 6567413
doi: 10.1186/s40425-019-0628-7
Thommen, D. S. et al. A transcriptionally and functionally distinct PD-1
pubmed: 29892065
pmcid: 6110381
doi: 10.1038/s41591-018-0057-z
Beltra, J. C. et al. Developmental relationships of four exhausted CD8
pubmed: 32396847
pmcid: 8360766
doi: 10.1016/j.immuni.2020.04.014
Scott, A. C. et al. TOX is a critical regulator of tumour-specific T cell differentiation. Nature 571, 270–274 (2019).
pubmed: 31207604
pmcid: 7698992
doi: 10.1038/s41586-019-1324-y
Philip, P. A. et al. A phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas. Future Oncol. 15, 3189–3196 (2019).
pubmed: 31512497
pmcid: 6854438
doi: 10.2217/fon-2019-0209
Tannir, N. M. et al. Efficacy and safety of telaglenastat plus cabozantinib vs placebo plus cabozantinib in patients with advanced renal cell carcinoma: rhe CANTATA randomized clinical trial. JAMA Oncol. 8, 1411–1418 (2022).
pubmed: 36048457
pmcid: 9437824
doi: 10.1001/jamaoncol.2022.3511
Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 72, 7–33 (2022).
pubmed: 35020204
doi: 10.3322/caac.21708
Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M. & Maitra, A. Pancreatic cancer: advances and challenges. Cell 186, 1729–1754 (2023).
pubmed: 37059070
doi: 10.1016/j.cell.2023.02.014
Ying, H. et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149, 656–670 (2012).
pubmed: 22541435
pmcid: 3472002
doi: 10.1016/j.cell.2012.01.058
Son, J. et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496, 101–105 (2013).
pubmed: 23535601
pmcid: 3656466
doi: 10.1038/nature12040
Morris, J. P. T. et al. α-Ketoglutarate links p53 to cell fate during tumour suppression. Nature 573, 595–599 (2019).
pubmed: 31534224
pmcid: 6830448
doi: 10.1038/s41586-019-1577-5
Zhao, R. et al. Biomarkers for pancreatic cancer based on tissue and serum metabolomics analysis in a multicenter study. Cancer Med. 12, 5158–5171 (2023).
pubmed: 36161527
doi: 10.1002/cam4.5296
Stuart, S. D. et al. A strategically designed small molecule attacks α-ketoglutarate dehydrogenase in tumor cells through a redox process. Cancer Metab. 2, 4 (2014).
pubmed: 24612826
pmcid: 4108059
doi: 10.1186/2049-3002-2-4
Zachar, Z. et al. Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo. J. Mol. Med. 89, 1137–1148 (2011).
pubmed: 21769686
doi: 10.1007/s00109-011-0785-8
Alistar, A. et al. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. Lancet Oncol. 18, 770–778 (2017).
pubmed: 28495639
pmcid: 5635818
doi: 10.1016/S1470-2045(17)30314-5
Halbrook, C. J. et al. Differential integrated stress response and asparagine production drive symbiosis and therapy resistance of pancreatic adenocarcinoma cells. Nat. Cancer 3, 1386–1403 (2022).
pubmed: 36411320
pmcid: 9701142
doi: 10.1038/s43018-022-00463-1
Daemen, A. et al. Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors. Proc. Natl Acad. Sci. USA 112, E4410–E4417 (2015).
pubmed: 26216984
pmcid: 4538616
doi: 10.1073/pnas.1501605112
Provenzano, P. P. et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21, 418–429 (2012).
pubmed: 22439937
pmcid: 3371414
doi: 10.1016/j.ccr.2012.01.007
Zhang, T., Ren, Y., Yang, P., Wang, J. & Zhou, H. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. Cell Death Dis. 13, 897 (2022).
pubmed: 36284087
pmcid: 9596464
doi: 10.1038/s41419-022-05351-1
Sherman, M. H. et al. Stromal cues regulate the pancreatic cancer epigenome and metabolome. Proc. Natl Acad. Sci. USA 114, 1129–1134 (2017).
pubmed: 28096419
pmcid: 5293019
doi: 10.1073/pnas.1620164114
Hwang, R. F. et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res. 68, 918–926 (2008).
pubmed: 18245495
pmcid: 2519173
doi: 10.1158/0008-5472.CAN-07-5714
Murray, E. R. et al. Disruption of pancreatic stellate cell myofibroblast phenotype promotes pancreatic tumor invasion. Cell Rep. 38, 110227 (2022).
pubmed: 35081338
pmcid: 8810397
doi: 10.1016/j.celrep.2021.110227
Kerk, S. A. et al. Metabolic requirement for GOT2 in pancreatic cancer depends on environmental context. Elife 11, e73245 (2022).
pubmed: 35815941
pmcid: 9328765
doi: 10.7554/eLife.73245
Drexler, K. et al. Cancer-associated cells release citrate to support tumour metastatic progression. Life Sci. Alliance 4, e202000903 (2021).
pubmed: 33758075
pmcid: 7994318
doi: 10.26508/lsa.202000903
Kim, P. K. et al. Hyaluronic acid fuels pancreatic cancer cell growth. Elife 10, e62645 (2021).
pubmed: 34951587
pmcid: 8730721
doi: 10.7554/eLife.62645
Olivares, O. et al. Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions. Nat. Commun. 8, 16031 (2017).
pubmed: 28685754
pmcid: 5504351
doi: 10.1038/ncomms16031
Schworer, S. et al. Fibroblast pyruvate carboxylase is required for collagen production in the tumour microenvironment. Nat. Metab. 3, 1484–1499 (2021).
pubmed: 34764457
pmcid: 8606002
doi: 10.1038/s42255-021-00480-x
Di Caro, G. et al. Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy. Gut 65, 1710–1720 (2016).
pubmed: 26156960
doi: 10.1136/gutjnl-2015-309193
Zhang, M. et al. Pancreatic cancer cells render tumor-associated macrophages metabolically reprogrammed by a GARP and DNA methylation-mediated mechanism. Signal Transduct. Target. Ther. 6, 366 (2021).
pubmed: 34711804
pmcid: 8553927
doi: 10.1038/s41392-021-00769-z
Boyer, S. et al. Multiomic characterization of pancreatic cancer-associated macrophage polarization reveals deregulated metabolic programs driven by the GM-CSF–PI3K pathway. Elife 11, e73796 (2022).
pubmed: 35156921
pmcid: 8843093
doi: 10.7554/eLife.73796
Mitchem, J. B. et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 73, 1128–1141 (2013).
pubmed: 23221383
doi: 10.1158/0008-5472.CAN-12-2731
Halbrook, C. J. et al. Macrophage-released pyrimidines inhibit gemcitabine therapy in pancreatic cancer. Cell Metab. 29, 1390–1399 (2019).
pubmed: 30827862
pmcid: 6602533
doi: 10.1016/j.cmet.2019.02.001
LaRue, M. M. et al. Metabolic reprogramming of tumor-associated macrophages by collagen turnover promotes fibrosis in pancreatic cancer. Proc. Natl Acad. Sci. USA 119, e2119168119 (2022).
pubmed: 35412885
pmcid: 9169723
doi: 10.1073/pnas.2119168119
Meiser, J. et al. Pro-inflammatory macrophages sustain pyruvate oxidation through pyruvate dehydrogenase for the synthesis of itaconate and to enable cytokine expression. J. Biol. Chem. 291, 3932–3946 (2016).
pubmed: 26679997
doi: 10.1074/jbc.M115.676817
Zhao, H. et al. Myeloid-derived itaconate suppresses cytotoxic CD8
pubmed: 36376563
pmcid: 10593361
doi: 10.1038/s42255-022-00676-9
Sherman, M. H. & Beatty, G. L. Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance. Annu. Rev. Pathol. 18, 123–148 (2023).
pubmed: 36130070
doi: 10.1146/annurev-pathmechdis-031621-024600
Brand, A. et al. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab. 24, 657–671 (2016).
pubmed: 27641098
doi: 10.1016/j.cmet.2016.08.011
Kumagai, S. et al. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer Cell 40, 201–218 (2022).
pubmed: 35090594
doi: 10.1016/j.ccell.2022.01.001
Bola, B. M. et al. Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport. Mol. Cancer Ther. 13, 2805–2816 (2014).
pubmed: 25281618
pmcid: 4258406
doi: 10.1158/1535-7163.MCT-13-1091
Kaymak, I. et al. Carbon source availability drives nutrient utilization in CD8
pubmed: 35981545
pmcid: 10068808
doi: 10.1016/j.cmet.2022.07.012
Elia, I. et al. Tumor cells dictate anti-tumor immune responses by altering pyruvate utilization and succinate signaling in CD8
pubmed: 35820416
pmcid: 9357162
doi: 10.1016/j.cmet.2022.06.008
Bantug, G. R. et al. Mitochondria-endoplasmic reticulum contact sites function as immunometabolic hubs that orchestrate the rapid recall response of memory CD8
pubmed: 29523440
pmcid: 6049611
doi: 10.1016/j.immuni.2018.02.012
Gerriets, V. A. et al. Metabolic programming and PDHK1 control CD4
pubmed: 25437876
doi: 10.1172/JCI76012
Danileviciute, E. et al. PARK7/DJ-1 promotes pyruvate dehydrogenase activity and maintains T
pubmed: 35618940
doi: 10.1038/s42255-022-00576-y
Vera-Badillo, F. E. et al. Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis. Eur. Urol. 67, 740–749 (2015).
pubmed: 24882670
doi: 10.1016/j.eururo.2014.05.010
Mandriota, S. J. et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1, 459–468 (2002).
pubmed: 12124175
doi: 10.1016/S1535-6108(02)00071-5
Maranchie, J. K. et al. The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1, 247–255 (2002).
pubmed: 12086861
doi: 10.1016/S1535-6108(02)00044-2
Maxwell, P. H. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271–275 (1999).
pubmed: 10353251
doi: 10.1038/20459
Semenza, G. L. HIF-1 mediates the Warburg effect in clear cell renal carcinoma. J. Bioenerg. Biomembr. 39, 231–234 (2007).
pubmed: 17551816
doi: 10.1007/s10863-007-9081-2
Courtney, K. D. et al. Isotope tracing of human clear cell renal cell carcinomas demonstrates suppressed glucose oxidation in vivo. Cell Metab. 28, 793–800 (2018).
pubmed: 30146487
pmcid: 6221993
doi: 10.1016/j.cmet.2018.07.020
Hakimi, A. A. et al. An integrated metabolic atlas of clear cell renal cell carcinoma. Cancer Cell 29, 104–116 (2016).
pubmed: 26766592
pmcid: 4809063
doi: 10.1016/j.ccell.2015.12.004
Mullen, A. R. et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 481, 385–388 (2011).
pubmed: 22101431
pmcid: 3262117
doi: 10.1038/nature10642
Yu, J. C., Jiang, Z. M. & Li, D. M. Glutamine: a precursor of glutathione and its effect on liver. World J. Gastroenterol. 5, 143–146 (1999).
pubmed: 11819414
pmcid: 4688527
doi: 10.3748/wjg.v5.i2.143
Abu Aboud, O. et al. Glutamine addiction in kidney cancer suppresses oxidative stress and can be exploited for real-time imaging. Cancer Res. 77, 6746–6758 (2017).
pubmed: 29021138
doi: 10.1158/0008-5472.CAN-17-0930
Gameiro, P. A. et al. In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metab. 17, 372–385 (2013).
pubmed: 23473032
pmcid: 4003458
doi: 10.1016/j.cmet.2013.02.002
Gross, M. I. et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol. Cancer Ther. 13, 890–901 (2014).
pubmed: 24523301
doi: 10.1158/1535-7163.MCT-13-0870
Huang, Q. et al. Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism. J. Biol. Chem. 293, 3535–3545 (2018).
pubmed: 29317493
pmcid: 5846160
doi: 10.1074/jbc.M117.810101
Harding, J. J. et al. A phase I dose-escalation and expansion study of telaglenastat in patients with advanced or metastatic solid tumors. Clin. Cancer Res. 27, 4994–5003 (2021).
pubmed: 34285061
pmcid: 9401498
doi: 10.1158/1078-0432.CCR-21-1204
Meric-Bernstam, F. et al. Telaglenastat plus cabozantinib or everolimus for advanced or metastatic renal cell carcinoma: an open-label phase I trial. Clin. Cancer Res. 28, 1540–1548 (2022).
pubmed: 35140121
doi: 10.1158/1078-0432.CCR-21-2972
Lee, C. H. et al. Telaglenastat plus everolimus in advanced renal cell carcinoma: a randomized, double-blinded, placebo-controlled, phase II ENTRATA Trial. Clin. Cancer Res. 28, 3248–3255 (2022).
pubmed: 35576438
pmcid: 10202043
doi: 10.1158/1078-0432.CCR-22-0061
Kaushik, A. K. et al. In vivo characterization of glutamine metabolism identifies therapeutic targets in clear cell renal cell carcinoma. Sci. Adv. 8, eabp8293 (2022).
pubmed: 36525494
pmcid: 9757752
doi: 10.1126/sciadv.abp8293
Okegawa, T. et al. Intratumor heterogeneity in primary kidney cancer revealed by metabolic profiling of multiple spatially separated samples within tumors. EBioMedicine 19, 31–38 (2017).
pubmed: 28408240
pmcid: 5440602
doi: 10.1016/j.ebiom.2017.04.009
Tang, C. et al. Immunometabolic coevolution defines unique microenvironmental niches in ccRCC. Cell Metab. 35, 1424–1440 (2023).
pubmed: 37413991
doi: 10.1016/j.cmet.2023.06.005
Gao, M., Monian, P., Quadri, N., Ramasamy, R. & Jiang, X. Glutaminolysis and transferrin regulate ferroptosis. Mol. Cell 59, 298–308 (2015).
pubmed: 26166707
pmcid: 4506736
doi: 10.1016/j.molcel.2015.06.011
Liu, B., Chen, X., Zhan, Y., Wu, B. & Pan, S. Identification of a gene signature for renal cell carcinoma-associated fibroblasts mediating cancer progression and affecting prognosis. Front. Cell Dev. Biol. 8, 604627 (2020).
pubmed: 33634098
doi: 10.3389/fcell.2020.604627
Lopez, J. I. et al. Fibroblast activation protein predicts prognosis in clear cell renal cell carcinoma. Hum. Pathol. 54, 100–105 (2016).
pubmed: 27063470
doi: 10.1016/j.humpath.2016.03.009
Peng, Y. L. et al. Single-cell transcriptomics reveals a low CD8
pubmed: 35121646
pmcid: 8819783
doi: 10.1136/jitc-2021-004206
Perillo, N. L., Pace, K. E., Seilhamer, J. J. & Baum, L. G. Apoptosis of T cells mediated by galectin-1. Nature 378, 736–739 (1995).
pubmed: 7501023
doi: 10.1038/378736a0
Bond, K. H. et al. The extracellular matrix environment of clear cell renal cell carcinoma determines cancer associated fibroblast growth. Cancers 13, 5873 (2021).
pubmed: 34884982
pmcid: 8657052
doi: 10.3390/cancers13235873
Young, M. D. et al. Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors. Science 361, 594–599 (2018).
pubmed: 30093597
pmcid: 6104812
doi: 10.1126/science.aat1699
Ge, J. et al. Glutaminolysis promotes collagen translation and stability via α-ketoglutarate-mediated mTOR activation and proline hydroxylation. Am. J. Respir. Cell Mol. Biol. 58, 378–390 (2018).
pubmed: 29019707
pmcid: 5854958
doi: 10.1165/rcmb.2017-0238OC
Hamanaka, R. B. et al. Glutamine metabolism is required for collagen protein synthesis in lung fibroblasts. Am. J. Respir. Cell Mol. Biol. 61, 597–606 (2019).
pubmed: 30973753
pmcid: 6827066
doi: 10.1165/rcmb.2019-0008OC
Cui, H. et al. Inhibition of glutaminase 1 attenuates experimental pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 61, 492–500 (2019).
pubmed: 30943369
pmcid: 6775943
doi: 10.1165/rcmb.2019-0051OC
Gibb, A. A. et al. Glutaminolysis is essential for myofibroblast persistence and in vivo targeting reverses fibrosis and cardiac dysfunction in heart failure. Circulation 145, 1625–1628 (2022).
pubmed: 35605036
pmcid: 9179236
doi: 10.1161/CIRCULATIONAHA.121.057879
McTague, A., Tazhitdinova, R. & Timoshenko, A. V. O-GlcNAc-mediated regulation of galectin expression and secretion in human promyelocytic HL-60 cells undergoing neutrophilic differentiation. Biomolecules 12, 1763 (2022).
pubmed: 36551191
pmcid: 9776088
doi: 10.3390/biom12121763
Braun, D. A. et al. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell 39, 632–648 (2021).
pubmed: 33711273
pmcid: 8138872
doi: 10.1016/j.ccell.2021.02.013
Chevrier, S. et al. An immune atlas of clear cell renal cell carcinoma. Cell 169, 736–749 (2017).
pubmed: 28475899
pmcid: 5422211
doi: 10.1016/j.cell.2017.04.016
Chakiryan, N. H. et al. Geospatial characterization of immune cell distributions and dynamics across the microenvironment in clear cell renal cell carcinoma. J. Immunother. Cancer 11, e006195 (2023).
pubmed: 37185232
pmcid: 10151991
doi: 10.1136/jitc-2022-006195
Fu, Q. et al. Tumor-associated macrophage-derived interleukin-23 interlinks kidney cancer glutamine addiction with immune evasion. Eur. Urol. 75, 752–763 (2019).
pubmed: 30293904
doi: 10.1016/j.eururo.2018.09.030
Tannahill, G. M. et al. Succinate is an inflammatory signal that induces IL-1β through HIF-1α. Nature 496, 238–242 (2013).
pubmed: 23535595
pmcid: 4031686
doi: 10.1038/nature11986
Reinfeld, B. I. et al. Cell-programmed nutrient partitioning in the tumour microenvironment. Nature 593, 282–288 (2021).
pubmed: 33828302
pmcid: 8122068
doi: 10.1038/s41586-021-03442-1
Webster, W. S. et al. Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival. Cancer 107, 46–53 (2006).
pubmed: 16708355
doi: 10.1002/cncr.21951
Giraldo, N. A. et al. Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. Clin. Cancer Res. 21, 3031–3040 (2015).
pubmed: 25688160
doi: 10.1158/1078-0432.CCR-14-2926
Senbabaoglu, Y. et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biol. 17, 231 (2016).
pubmed: 27855702
pmcid: 5114739
doi: 10.1186/s13059-016-1092-z
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48–61 (2015).
pubmed: 25594174
pmcid: 4856474
doi: 10.1016/j.cell.2014.12.033
Giraldo, N. A. et al. Tumor-infiltrating and peripheral blood t-cell immunophenotypes predict early relapse in localized clear cell renal cell carcinoma. Clin. Cancer Res. 23, 4416–4428 (2017).
pubmed: 28213366
doi: 10.1158/1078-0432.CCR-16-2848
Carr, E. L. et al. Glutamine uptake and metabolism are coordinately regulated by ERK/MAPK during T lymphocyte activation. J. Immunol. 185, 1037–1044 (2010).
pubmed: 20554958
doi: 10.4049/jimmunol.0903586
Johnson, M. O. et al. Distinct regulation of T
pubmed: 30392958
pmcid: 6361668
doi: 10.1016/j.cell.2018.10.001
Madden, M. Z. et al. Differential effects of glutamine inhibition strategies on antitumor CD8 T cells. J. Immunol. 211, 563–575 (2023).
pubmed: 37341499
doi: 10.4049/jimmunol.2200715
Au, L. et al. Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer Cell 39, 1497–1518 (2021).
pubmed: 34715028
pmcid: 8599450
doi: 10.1016/j.ccell.2021.10.001
Leone, R. D. et al. Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. Science 366, 1013–1021 (2019).
pubmed: 31699883
pmcid: 7023461
doi: 10.1126/science.aav2588
Kim, J. & DeBerardinis, R. J. Mechanisms and implications of metabolic heterogeneity in cancer. Cell Metab. 30, 434–446 (2019).
pubmed: 31484055
pmcid: 6730674
doi: 10.1016/j.cmet.2019.08.013
Cantor, J. R. et al. Physiologic medium rewires cellular metabolism and reveals uric acid as an endogenous inhibitor of UMP synthase. Cell 169, 258–272 (2017).
pubmed: 28388410
pmcid: 5421364
doi: 10.1016/j.cell.2017.03.023
Rossiter, N. J. et al. CRISPR screens in physiologic medium reveal conditionally essential genes in human cells. Cell Metab. 33, 1248–1263 (2021).
pubmed: 33651980
pmcid: 8172426
doi: 10.1016/j.cmet.2021.02.005
Lemberg, K. M., Vornov, J. J., Rais, R. & Slusher, B. S. We’re not ‘DON’ yet: optimal dosing and prodrug delivery of 6-diazo-5-oxo-L-norleucine. Mol. Cancer Ther. 17, 1824–1832 (2018).
pubmed: 30181331
pmcid: 6130910
doi: 10.1158/1535-7163.MCT-17-1148
Wathoni, N. et al. Monoclonal antibody as a targeting mediator for nanoparticle targeted delivery system for lung cancer. Drug Deliv. 29, 2959–2970 (2022).
pubmed: 36085575
pmcid: 9467540
doi: 10.1080/10717544.2022.2120566
Gao, J., Liang, Y. & Wang, L. Shaping polarization of tumor-associated macrophages in cancer immunotherapy. Front Immunol. 13, 888713 (2022).
pubmed: 35844605
pmcid: 9280632
doi: 10.3389/fimmu.2022.888713
Lopes-Coelho, F., Martins, F., Pereira, S. A. & Serpa, J. Anti-angiogenic therapy: current challenges and future perspectives. Int. J. Mol. Sci. 22, 3765 (2021).
pubmed: 33916438
pmcid: 8038573
doi: 10.3390/ijms22073765
Hauge, A. & Rofstad, E. K. Antifibrotic therapy to normalize the tumor microenvironment. J. Transl. Med 18, 207 (2020).
pubmed: 32434573
pmcid: 7240990
doi: 10.1186/s12967-020-02376-y
Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20, 651–668 (2020).
pubmed: 32433532
pmcid: 7238960
doi: 10.1038/s41577-020-0306-5